Response Monitoring Schedule During Treatment of Patients with Chronic Myeloid Leukemia
The response monitoring schedule for the assessment of therapeutic efficacy includes assessment of hematological, cytogenetic, and molecular responses at defined time-points (see Table 1 ). [1] [2] [3] Assessment of the molecular response is considered particularly important in CML therapy as it can provide valuable information in the follow-up of CML patients. For instance, it has been correlated with cytogenetic response, 4, 5 and has been shown to be a predictor of progression-free survival 6 and relapse. 2 Molecular response is assessed by measuring the bcr-abl transcript levels. The transcript bcr-abl levels in samples of both bone marrow and peripheral blood of Ph + CML patients have been correlated to the number of residual leukemic cells in the sample (see Figure 1 ). 2 Realtime quantitative polymerase chain reaction (RQ-PCR) is used to measure transcript levels; this technique is very sensitive, being able to detect a single bcr-abl-positive cell among up to 10 5 -10 6 normal cells. 4, 7, 8 domain at the adenosine triposphate (ATP)-binding site and trapping the protein in an inactive conformation. The International Randomized
Study of Interferon and ST1571 (IRIS) trial established imatinib as the standard initial therapy for patients with chronic-phase CML (CML-CP).
Newly diagnosed CML-CP patients (n=1,106) were randomized to receive either imatinib (400mg daily [QD] ) or IFN-α) plus cytarabine (Ara-C). The study showed a significantly greater complete cytogenetic response (CCyR) rate in imatinib-treated patients compared with patients who were administered first-line therapy with IFN-α plus lowdose Ara-C (76.2 versus 14.5%; p<0.001; median follow-up 19 months). 9 Freedom from progression to more advanced-stage disease was higher in the imatinib group compared with the IFN-α group (96.7 versus 91.5%; p<0.001), and five-and six-year follow-up data showed that these responses were durable in the majority of the patients who received continuous imatinib treatment. 6, 10 The long-term survival associated with imatinib exceeds the reported overall survival (OS) for all other CML therapies. The six-year OS rate in the imatinib group was estimated at 88%, while it was 95% when considering only CML-related deaths. 10 Imatinib is currently approved by the US Food and Drug Resistance to TKIs may develop in some patients with CML and is manifested by either a suboptimal response to or failure of therapy.
Primary resistance to imatinib (failure to achieve the desired response at specified times despite having adequate treatment) is rare and may be due to inadequate imatinib dose (i.e. lack of patient compliance to the drug). [11] [12] [13] Secondary resistance or loss of response may arise from acquired resistance to bcr-abl inhibition, which may be due to diverse mechanisms of resistance to TKIs. Mechanisms of resistance include decreased imatinib bioavailability or cell exposure, bcr-abl oncogene amplification or overexpression, point mutations within the ABL activation site, and cytogenetic clonal evolution. [14] [15] [16] Fewer than 5% of Ph + CP-CML patients per year exhibit imatinib resistance. Imatinib resistance primarily occurs in the advanced phases of Ph + CML and appears within three to six months of initiating therapy. 17 Some studies have associated imatinib resistance with poor prognosis, 18 while others have found that patient prognosis is dependent on disease stage and not mutational status. 19 The IRIS study showed that the number of patients who progress to advanced disease declines over time, and early treatment may prevent progression.
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Imatinib Dose Escalation to Optimize Imatinib Therapy
Imatinib dose escalation has been investigated in patients who do not respond to standard dose as no dose-limiting toxicities have been found at a higher dose of imatinib. 20 The rationale for this strategy is that mutations resulting in the overexpression and amplification of bcr-abl could potentially be overcome by higher concentrations of imatinib.
2,17
Although there is evidence on the efficacy of imatinib dose escalation (600-800mg QD), in some studies responses were short-lived. 21 
trial that indicated that imatinib dose escalation to 800mg QD may effectively treat patients with CML-CP who fail to achieve a cytogenetic response to standard-dose imatinib. 25 Imatinib dose escalation from 400 to 600mg QD is FDA-approved in the US for patients with CML-CP. The NCCN recommends dose escalation to a maximum of 800mg QD in patients with CML who fail standard-dose imatinib as well as those who achieve only a suboptimal response with first-line therapy with standard-dose imatinib at specified time-points. 
Dasatinib
Dasatinib is an orally available dual inhibitor of the bcr-abl/SRC kinases.
It can bind the ABL kinase in both the inactive and the active conformation 26, 27 and has a 325-fold greater binding than imatinib against unmutated bcr-abl in vitro. 26 The SRC/ABL Tyrosine kinase Table 2 ). Progression-free survival (PFS) and OS rates at two-year follow-up were 80 and 94%, respectively, in patients with chronic-phase disease, 39 while a PFS rate of 76% was noted in patients with CML-AP at eight-month follow-up. 29 In the international openlabel, randomized START-R phase II study, dasatinib (70mg BID) was
shown to induce greater and more durable CCyR in patients with 400-600mg QD imatinib-resistant or -intolerant CML-CP compared with imatinib dose escalation to 800mg QD. 31, 40 Data from the START trials also demonstrated high major molecular response (MMR) rates in dasatinib-treated patients, with 12, 22, 35, and 40% of patients achieving an MMR after three, six, 12, and 24 months of follow-up, respectively. 41 Some of the most common grade 3/4 adverse effects associated with dasatinib are summarized in Table 3 . Table 4 . 44, 47, 48 Compared with historical controls of imatinib, six months of nilotinib treatment resulted in earlier MMRs, with higher rates than achieved with imatinib (see Table 5 ). Nilotinib was generally well-tolerated in this study (see Table 3 3 Nilotinib has also been evaluated in patients with imatinib-resistant or -intolerant Ph + CML-BP.
Preliminary data show activity of nilotinib (400mg BID), with a 12-month OS rate of 42%. 48 However, disease progression resulted in a discontinuation rate of more than 50%.
Choosing Between Second-generation Tyrosine Kinase Inhibitors
The NCCN guidelines for CML state that the choice between the approved second-generation TKIs dasatinib and nilotinib should be based on several practical considerations, 3 including the side-effect profile of the drug, patient comorbidities, drug-drug interactions, type and stage of disease, mutational status, and other practical considerations.
It is vital to consider the side-effect profile of both dasatinib and nilotinib (see Table 3 ) when selecting the appropriate second-line therapy. Importantly, there is a risk for pleural effusion with dasatinib, especially in patients with prior cardiac history and hypertension, patients (see Table 6 ). 62, 63 In the future, as more data become available, identification of the type of mutation present may help to identify the subset of patients with CML most likely to benefit from nilotinib, dasatinib, or newer drugs. At present, current guidelines indicate that the choice of second-line agent should primarily be driven by clinical risk-benefit profile rather than the results of mutational analysis, with the exception of the T315I mutation. 12 40
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Nilotinib (400mg BID) The previously mentioned dasatinib phase III START-R study suggested that patients with CML-CP showing suboptimal response to prior imatinib therapy might benefit from dasatinib. 45 Furthermore, a recent analysis of a trial in CML-CP patients showed that earlier initiation of treatment with dasatinib after relapse during imatinib therapy led to extended PFS and higher response rates. 73 Results from an ongoing trial (NCT00320190) 74 comparing the efficacy of dasatinib versus imatinib dose escalation in patients with suboptimal response to standard-dose imatinib should further address this treatment strategy. Further research should identify whether this novel approach of changing treatment from imatinib to the second-line agents at an earlier time-point (i.e. after suboptimal response) is a viable strategy.
Options Under Investigation for First-line Treatment of Chronic-phase Disease
High-dose imatinib (600-800mg QD) has been evaluated in newly diagnosed previously untreated CML-CP patients and has been associated with moderate to high cytogenetic and molecular responses. 64, 75, 76 High-dose imatinib has also been shown to induce increased CCyR and molecular responses compared with standard-dose imatinib. 64 In a study where 114 patients with newly diagnosed CML-CP were treated with 400mg BID imatinib, no patients progressed to advanced disease stages at a median follow-up of 15 months, and the two-year OS was estimated at 94%. 64 The efficacy and tolerability of both dasatinib and nilotinib have led to 
